Clinical Trial Update: Regorafenib in Patients With Refractory Primary Bone Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating regorafenib in patients with refractory primary bone tumors, including osteosarcoma and Ewing sarcoma of bone; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Osteosarcoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Institute of Mother and Child, Warsaw, Poland | Conditions: Osteosarcoma, Ewing Sarcoma of Bone | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING